Puma Biotechnology logo Puma Biotechnology (NASDAQ:PBYI) had its price target cut by investment analysts at Citigroup from $164.00 to $146.00 in a research note issued on Wednesday, January 24th. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s …
0 Comments